DURHAM–Phitonex Inc., a Duke spin-out developing the next generation of fluorescent labels and instrumentation to advance the fight against disease, has raised $175,000 in a debt offering, according to a filing with the U.S. Securities and Exchange Commission.
Phitonex reagents provide a cost-effective, non-destructive method to obtain more information about critical molecular biomarkers, simplifying experimental design and accelerating the discovery process, according to its web site.
The company is currently developing two product lines: a suite of extraordinarily bright labels spanning the entire visible spectrum, and a new class of fluorescent labels and instrumentation that together increase the number of simultaneously observable molecular biomarkers by 5-10 times that of existing high channel count systems.
Disease diagnosis and treatment is currently constrained by limitations of the fluorescent labels used to observe molecular biomarkers. They are limited brightness and limited colors.
Phitonex says it is actively seeking seed funding to launch their bright labels in 2019, accelerate the production of their high channel count labels and systems, and grow the company.
Phitonex says it solves these problems by introducing new fluorescent labels and instrumentation. NovaFluors are a suite of ultra-bright labels spanning the entire visible spectrum, perfect for observing low-abundance molecular biomarkers.
InfiniFluor avoid the spectral overlap constraints of typical labels, and work in conjunction with its InfiniSight instrumentation to increase the number of simultaneously observable molecular biomarkers.
